DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
49 hedge funds and large institutions have $8.58M invested in DMK Pharmaceuticals Corporation Common Stock in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 9 closing their positions.
814% more call options, than puts
Call options by funds: $914K | Put options by funds: $100K
133% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 6
6% less funds holding
Funds holding: 52 → 49 (-3)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
41% less capital invested
Capital invested by funds: $14.6M → $8.58M (-$6.03M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$294K |
| 2 |
JP Morgan Chase
New York
|
+$171K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$85K |
| 4 |
Morgan Stanley
New York
|
+$28.7K |
| 5 |
Jane Street
New York
|
+$27.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$801K |
| 2 |
Millennium Management
New York
|
-$373K |
| 3 |
GC
Greenlight Capital
New York
|
-$283K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$36.2K |
| 5 |
PCM
Prelude Capital Management
New York
|
-$28K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
51
Credit Suisse
Zurich,
Switzerland
| – | -$24K | -355 | Closed |
|
52
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$19K | -286 | Closed |
|
|
RJA
53
Raymond James & Associates
St Petersburg,
Florida
| – | -$16K | -232 | Closed |
|
54
Barclays
London,
United Kingdom
| – | -$8K | -105 | Closed |
|
|
FCM
55
Firestone Capital Management
Coral Gables,
Florida
| – | -$6K | -74 | Closed |
|
|
HCP
56
Hexagon Capital Partners
Rogers,
Arkansas
| – | -$5K | -71 | Closed |
|
|
HI
57
Harbour Investments
Madison,
Wisconsin
| – | -$2K | -29 | Closed |
|
DMK Hedge Fund Activity: Q4 2021 in Review
49 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q4 2021, worth a combined $8.58M — down 41% from $14.6M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of DMK and 6 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 14 added.
The largest buyer was Citadel Advisors, adding an estimated $294K. The largest seller was Susquehanna International Group, cutting an estimated $801K.
- 49 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q4 2021, down from 52 in Q3 2021.
- Funds reported $8.58M of DMK Pharmaceuticals Corporation Common Stock stock for Q4 2021, down 41% quarter-over-quarter.
- 6 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q4 2021 and 9 closed out, a net change of -3 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q4 2021 was Citadel Advisors, an estimated $294K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q4 2021 was Susquehanna International Group, an estimated $801K sold.
Based on aggregated 13F filings for Q4 2021.